Clinical trials
Dermatitis clinical trials
Below are recruiting dermatitis clinical trials, each written for real people, not researchers. We’re tracking 220 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07022288Recruiting
Study of La Roche-Posay cream for mild facial eczema
This study tests whether a specific soothing moisturizer (La Roche-Posay B5 cream) helps people with mild, stable facial eczema. It is a simple, low-risk trial using a cream you can apply at home.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07015762RecruitingPhase 1
Testing IBI3002 for moderate-to-severe eczema
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
Suzhou, JiangsuAges 18–65 - NCT07003425RecruitingPhase 2
Long-term safety and effectiveness of APG777 for eczema
This study looks at the long-term safety and how well APG777 works for people with eczema (atopic dermatitis). It is for people who have already completed treatment with APG777 in an earlier study and may benefit from continuing it.
Fountain Valley, CaliforniaAges 18 years+ - NCT06998446Recruiting
Sodium in the skin and eczema study
This study looks at sodium levels in the skin of older adults with eczema. It uses an MRI scan to measure sodium and may help us understand how sodium affects eczema severity.
San Francisco, CaliforniaAges 50 years+ - NCT06988605Recruiting
Nemolizumab for teens and adults with moderate-to-severe eczema
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
Birmingham, AlabamaAges 12 years+ - NCT06982352RecruitingPhase 1
Testing safety of LPX-TI641 for eczema and psoriasis
This study tests a new drug called LPX-TI641 to see if it's safe and how it works in people with atopic dermatitis (eczema) or psoriasis. If you have moderate-to-severe symptoms that haven't been helped by standard creams, you might be able to join.
Fargo, North DakotaAges 18 years+ - NCT06957444Enrolling by invitation
Allergic skin reactions and scar appearance after joint replacement
This study looks at how often patients have an allergic skin reaction to the stitches used after knee or hip replacement, and how their scar looks. If you are having a first-time replacement, you may be able to join.
Morgantown, West VirginiaAges 18–80 - NCT06958003Enrolling by invitation
Preventing and treating diaper rash in the NICU with air time
This study is testing whether giving babies in the NICU time without a diaper (air time) helps prevent or treat diaper rash. It is for babies who are at least 30 weeks old at birth, up to 1 year old, and in stable condition.
Cincinnati, OhioAges 7 months–1 year - NCT06313333Recruiting
National registry for moderate to severe adult atopic dermatitis
This registry tracks adults with moderate to severe atopic dermatitis (eczema) over time. It helps doctors learn more about the disease and how treatments work in real life.
Brescia, BresciaAges 18 years+ - NCT06947252Enrolling by invitation
Food allergy test for kids with eczema avoiding certain foods
This trial tests if children with eczema who avoid certain foods actually have a food allergy. It uses a supervised oral food challenge to confirm.
BangkokAges Up to 6 years - NCT06947980RecruitingPhase 2
Study of CM512 for moderate-to-severe atopic dermatitis
This trial tests a new treatment called CM512 for people with moderate-to-severe eczema (atopic dermatitis). It aims to see if the drug can improve skin symptoms like itching and rash.
BeijingAges 18–75 - NCT06947993RecruitingPhase 2
Study of a new treatment for moderate to severe eczema
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
Birmingham, AlabamaAges 18–100 - NCT06946641RecruitingPhase 1
Testing QLS12010 safety in healthy adults and people with eczema
This trial tests a new drug, QLS12010, to see if it is safe and how it works in healthy volunteers and in people with moderate to severe atopic dermatitis (eczema). It may offer a new treatment option for those whose eczema has not improved with topical creams.
BeijingAges 18–75 - NCT06931990RecruitingPhase 1/Phase 2
Testing a new tablet for eczema in Chinese adults
This trial tests an experimental tablet (LT-002-158) for adults with moderate-to-severe eczema that hasn't improved enough with standard creams. The goal is to see if the tablet is safe and helps control symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT06934252RecruitingPhase 1
Study of TRB-061 for atopic dermatitis (eczema)
This trial tests an investigational drug called TRB-061 in healthy adults and people with atopic dermatitis (eczema). It aims to see if the drug is safe and how the body processes it. If you have moderate to severe eczema that started at least a year ago, you may be able to join the patient part of the study.
Belconnen, Australian Capital TerritoryAges 18–70 - NCT06880276RecruitingPhase 3
Studying QLM3003 ointment for mild or moderate eczema
This trial tests if an ointment called QLM3003 is safe and helps adults with mild to moderate atopic dermatitis (eczema). It may be a new treatment option for people whose eczema affects small areas of skin.
ShenyangAges 18–75 - NCT06837831Recruiting
Mepilex Lite Dressing for radiation skin damage on anal area
This trial tests a special wound dressing (Mepilex Lite) to treat skin burns from radiation therapy in patients with rectal cancer. It may help heal the skin around the anal canal more comfortably.
Jinan, ShandongAges 18 years+ - NCT06808477RecruitingPhase 1
BBT001 for moderate to severe eczema
This trial tests an experimental drug called BBT001 for people with moderate to severe eczema (atopic dermatitis) that hasn't been helped enough by creams. The study is in early phases, so it will check how safe the drug is and how well it might work.
Irvine, CaliforniaAges 18–72 - NCT06801821Recruiting
Stigma study on skin conditions
This study looks at how people view those with certain skin conditions. It aims to understand stigma, which may help improve awareness and support.
Roma, ItaliaAges 18 years+ - NCT03361215Recruiting
Tracking skin disease patterns and anti-inflammatory response
This study looks at how atopic dermatitis (eczema), psoriasis, or other autoimmune skin diseases change over time and how the body responds to anti-inflammatory signals. Your information and—if eligible—samples help researchers find patterns that could guide better treatments.
KielAges birth–100 years - NCT06775860RecruitingPhase 3
Testing ICP-332 for moderate to severe eczema
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
Hefei, AnhuiAges 18–75 - NCT06755307Recruiting
Probiotic cream for diaper rash in babies
This study tests whether a probiotic (beneficial bacteria) cream can help heal diaper rash in babies. It's for otherwise healthy infants under 2 who have diaper dermatitis.
MariborAges 1 month–2 years - NCT06723080RecruitingPhase 3
Oral VC005 for moderate to severe eczema
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Nanjing, JiangsuAges 18–75 - NCT06715982RecruitingPhase 2
JAK inhibitor for severe skin rash from immunotherapy
This study tests a JAK inhibitor pill for people with severe skin rashes caused by immunotherapy drugs like Keytruda or Opdivo. It aims to help control the rash and allow you to keep benefiting from your cancer treatment.
Quzhou, ZhejiangAges 18–80
Hear when a new Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for dermatitis?
- Yes. Clin2 currently lists 220 recruiting dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.